Diabetes treatment may also provide protection against endometrial cancer

Apr 05, 2011
This is Dr. Harpal Randeva of Warwick Medical School. Credit: University of Warwick Medical

Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also in women with Polycystic vary syndrome (PCOS), may potentially provide protection against endometrial cancer.

Endometrial cancer is the most common of the female genital tract and the fourth most common cancer in women in the UK and the US. Up to a third of PCOS women also have endometrial which, in turn predisposes these women to endometrial cancer. PCOS affects 5%-10% of women of reproductive age, where Metformin ameliorates and hyperinsulinemia in these women, but also long-term use of Metformin improves ovulation and regularity.

Recent research has found that Metformin has anti-cancer properties e.g. in . Given that insulin resistant states, e.g. obesity, diabetes and PCOS are more at risk of developing endometrial cancer, the Warwick researchers studied the effects of metformin treatment on endometrial cancer cells. The researchers used serum from control and PCOS (before and after metformin treatment) subjects and carried out basic scientific experiments on endometrial cancer cells. The experiments revealed a decrease in endometrial cancer cell invasiveness in sera from metformin treated PCOS women.

The researchers found that serum samples from PCOS women who had completed the 6 month course of Metformin the rate of spread of endometrial cancer cells was around 25% lower than in the serum samples from PCOS women who had not started that treatment.

The principal investigators, Dr Harpal Randeva and Dr Bee K Tan, at Warwick Medical School said:
"We are very excited about our findings, which reveal the significant impact of Metformin therapy use on human endometrial cancer cells. However, it is prudent that further research to explore if would actually be beneficial clinically as adjuvant therapy in endometrial cancer; this would need to be addressed through a randomized controlled trial."

Explore further: New chemical technology boosts potency of targeted cancer therapy

More information: The research paper has been published in the The Journal of Clinical Endocrinology & Metabolism - doi:10.1210/jc.2010-1803

Related Stories

Diabetes drug slows early-onset puberty in girls

Jun 16, 2008

In young girls at risk of early puberty and insulin resistance, the diabetes drug metformin delayed the onset of menstruation and decreased the development of insulin resistance, a risk factor for type 2 diabetes, according ...

Exercise may reduce risk of endometrial cancer

Nov 09, 2010

Women who exercise for 150 minutes a week or more may see a reduced risk of endometrial cancer, despite whether or not they are overweight, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention ...

Recommended for you

Using healthy skin to identify cancer's origins

14 hours ago

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

Gender differences in receipt of end-of-life care

15 hours ago

(HealthDay)—There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to ...

Scientists unveil prostate cancer's 'Rosetta Stone'

16 hours ago

Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.